Bellde­grun teams with a group of top VC play­ers to un­veil a $295M biotech fund at Vi­da Ven­tures

Arie Bellde­grun didn’t just co-found a new biotech with $300 mil­lion in fi­nanc­ing. He al­so is tak­ing the wraps off a new ven­ture fund with $295 mil­lion to in­vest in what he and his part­ners hope will be the next-gen biotech com­pa­nies to watch. 

The new fund is called Vi­da Ven­tures, based in Boston, and one of its first in­vest­ments went to Bellde­grun’s lat­est CAR-T cre­ation, Al­lo­gene. Ho­mol­o­gy Med­i­cines, Prax­is Pre­ci­sion Med­i­cines and Pi­o­nyr Im­munother­a­peu­tics are al­so in the port­fo­lio af­ter get­ting start­ed last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER